Pharmigene, Inc. (TPEX: 7595)
Health Care · Biotechnology · TW
NT$7.25
-2.03% today · -33.8% 1Y
Pharmigene, Inc. (TPEX: 7595) operates in the Biotechnology industry within the Health Care sector. The company is valued at $11.28M and employs 49 people.
Over the last twelve months the share price has lost 33.8%, trading between 5.90 and 11.85.
Tweenvest scores Pharmigene, Inc. across four factors: quality 54/100, value 50/100, growth 74/100. Its strongest factor is growth.
7595 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.28M
- Revenue (TTM)
- $5.91M
- P/E
- —
- EPS
- -1.04
- Dividend yield
- —
- Beta (5Y)
- 0.00
- 52-week high
- NT$11.85
- 52-week low
- NT$5.90
- Avg volume (3M)
- —
- Shares outstanding
- 50.47M
- Employees
- 49
- Next earnings
- —
About Pharmigene, Inc.
Pharmigene, Inc. operates globally, specializing in the creation, production, and distribution of diagnostic testing solutions. Its offerings include molecular diagnostic tools specifically designed to detect adverse drug reactions, alongside DNA extraction products crucial for diverse applications such as gene expression analysis, clinical molecular diagnostics, human identity verification, forensic investigations, and biomedical research. The firm also provides an array of specialized services, including pharmacogenomics, drug allergy screening, and functional medicine assessments. Beyond its own products, Pharmigene distributes various genomics and genetics equipment and reagents. Complementing these, it offers a comprehensive suite of support solutions, encompassing expert consultation, training programs, analytical software, and technical assistance. Furthermore, the company extends its capabilities through Contract Development and Manufacturing Organization (CDMO) services. Pharmigene, founded in 1994, is headquartered in Taipei, Taiwan.
- ISIN
- TW0007595B13
- Founded
- 2005
- Listed since
- Dec 22, 2020
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Aelis Farma SAENXTPA: AELIS | $11.50M | €0.75 | -5.88% |
| Pluri Inc.NasdaqCM: PLUR | $11.48M | $0.93 | -2.44% |
| Celyad Oncology SAENXTBR: CYAD | $11.43M | €0.23 | +13.50% |
| NGeneBio Co., Ltd.KOSDAQ: A354200 | $11.31M | ₩937.00 | +18.91% |
| Passage Bio, Inc.NasdaqCM: PASG | $11.26M | $3.50 | -5.15% |
| Patrys LimitedASX: PAB | $11.06M | AU$0.03 | -3.57% |
| IN8bio, Inc.NasdaqCM: INAB | $10.94M | $1.11 | -17.16% |
| Intensity Therapeutics, Inc.NasdaqCM: INTS | $10.94M | $3.35 | -7.71% |
Figures last refreshed Oct 18, 2026.